SEMAGLUTIDE 10MG | GLP-1 Weight Loss & Diabetes

Semaglutide 10mg is a research-grade GLP-1 receptor agonist studied for weight loss, glycaemic control, appetite suppression and cardiovascular risk factors. This 3 ml vial containing 10 mg presentation is intended for laboratory investigation of mid-range GLP-1 receptor pharmacology. Semaglutide binds the GLP-1 receptor and activates cAMP-dependent signalling in pancreatic beta cells, the hypothalamus and the brainstem. Albumin binding protects it from rapid renal clearance and DPP-4 degradation, producing a week-long duration of action. At the 10 mg presentation, studies typically examine intermediate exposures that bridge tolerability and efficacy ranges.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed that semaglutide 2.4 mg weekly reduced body weight by about 15% at 68 weeks. The SUSTAIN programme established dose-dependent glycaemic benefits in type 2 diabetes. Researchers use this presentation for studies of body composition, insulin sensitivity, cardiovascular markers and hepatic fat. It is also a comparator for dual and triple incretin agonists. The 10 mg vial supports multi-arm rodent studies and cell-based signalling assays at intermediate concentrations. Because the peptide adsorbs to surfaces, use low-binding tubes and include a carrier protein if the protocol permits.

Keep the sealed vial at -20C until use, shield it from light, and reconstitute under sterile conditions with bacteriostatic water or the buffer specified in the study protocol. Working solutions should be kept cold, aliquoted, and used within the stability window established for that peptide. Key questions concern the dose-response separation of weight loss from nausea, the durability of effects after discontinuation, and the impact on lean mass and bone density. Sold for laboratory research only. Not for human or veterinary use, and not for diagnostic or therapeutic applications.